Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Holding ESPR?
Track your performance easily
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)6.79M
Market Cap
$413.77M
Enterprise Value$736.50M
Total Cash (Recent Filing)$211.58M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta2.89
Next Earnings
Feb 27, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding197,035,170
10 Day Avg. Volume5,779,610
30 Day Avg. Volume6,791,401
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit10.08
Enterprise Value/Ebitda-13.08
Forecast
1Y Price Target
$7.13Price Target Upside298.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Esperion News
Bulls Say, Bears Say
Bulls Say
Drug EffectivenessEsperion's non-statin drugs, NEXLETOL and NEXLIZET, have shown significant reductions in LDL-C, hsCRP, and risk of cardiovascular events, which supports their approval as effective treatments.
Market ExpansionEsperion has strengthened future global growth by engaging with payers, physicians, and healthcare professionals, leading to increased commercial and Medicare coverage.
Regulatory And Commercial ProgressThe Nexletol and Nexlizet labels were expanded to include a cardiovascular risk reduction indication in statin intolerant patients, increasing the addressable population to about 70 million patients in the US.
Bears Say
CompetitionThe topic of competition for the company's bempedoic acid franchise is becoming increasingly relevant, with several competitors emerging on the horizon.
Financial PerformanceEsperion had a challenging 3Q with total revenues slightly missing expectations and sales of bempedoic acid falling short by 10%.
Pipeline ConcernsA lack of a mid/late stage pipeline is an overhang as an end of decade loss of exclusivity looms.
---
Ownership Overview
0.99% Insiders
18.40% Mutual Funds
0.05% Other Institutional Investors
70.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $1.58 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $413.77M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Feb 27, 2025 which is in 25 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.025.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.13.
How many shares outstanding does Esperion have?
Esperion has 197,035,170 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -4.525%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Woodline Partners LP. It holds Esperion’s shares valued at 4M.
---
Esperion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.13 (298.32% Upside)
$7.13 (298.32% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.44%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Esperion has shown strong prescription growth and expanded payer access, both domestically and internationally. While facing some financial headwinds due to contract updates, the company is on track for future growth with a strengthened financial position.Read More>---
ESPR Stock 12 Month Forecast
Average Price Target
$7.13
▲(298.32% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
9/24 ratings generated profit
1 Year Average Return
+38.18%
reiterated a buy rating 11 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +38.18% per trade.
---